ID   IGR-CaP1-R100
AC   CVCL_IR45
DR   cancercelllines; CVCL_IR45
DR   Wikidata; Q54897377
RX   Patent=US8674172;
RX   PubMed=24525428;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4127.
CC   Selected for resistance to: ChEBI; CHEBI_4672; Docetaxel anhydrous (Taxotere).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
ST   Source(s): Patent=US8674172
ST   Amelogenin: X
ST   CSF1PO: 11,12,14,15,16
ST   D13S317: 8,10
ST   D16S539: 10,11,12,13
ST   D18S51: 15,16
ST   D19S433: 13,14
ST   D21S11: 26,30.2
ST   D2S1338: 17,24,25
ST   D3S1358: 14,15
ST   D5S818: 12,13
ST   D7S820: 9.1,10.1,11.2
ST   D8S1179: 13,14,16,17
ST   FGA: 19,20,21,25
ST   TH01: 6,7,8,9.3
ST   TPOX: 8,10,11
ST   vWA: 16,20,21
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A018 ! IGR-CaP1
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 19-12-24; Version: 11
//
RX   PubMed=24525428; DOI=10.18632/oncotarget.1574; PMCID=PMC3996665;
RA   Al Nakouzi, Nader
RA   Cotteret, Sophie
RA   Commo, Frederic
RA   Gaudin, Catherine
RA   Rajpar, Shanna
RA   Dessen, Philippe
RA   Vielh, Philippe
RA   Fizazi, Karim
RA   Chauchereau, Anne
RT   "Targeting CDC25C, PLK1 and CHEK1 to overcome docetaxel resistance
RT   induced by loss of LZTS1 in prostate cancer.";
RL   Oncotarget 5:667-678(2014).
//
RX   Patent=US8674172;
RA   Chauchereau, Anne
RA   Fizazi, Karim
RA   Gaudin, Catherine
RA   Al Nakouzi, Nader
RA   Benard, Jean
RT   "Prostate cancer cell lines and their use in screening method.";
RL   Patent number US8674172, 18-Mar-2014.
//